Verum Health
Recovery / Nerve Protocol

ARA-290 · 5ML

ARA-290 is a non-erythropoietic EPO receptor agonist studied for neuroprotection, anti-inflammation, tissue repair, and peripheral nerve recovery. Physician-reviewed. Prescription required.

Recovery Neuroprotection Prescription Required
What It Is
ARA-290 5ML

Mechanism of Action

ARA-290 is a synthetic peptide derived from the tissue-protective region of Erythropoietin. It was designed to retain EPO's cytoprotective and anti-inflammatory effects without stimulating red blood cell production. Its mechanisms involve activation of a distinct receptor complex that triggers tissue protection, anti-inflammation, and repair pathways.

This selectivity allows ARA-290 to deliver cytoprotective, anti-inflammatory, and repair-promoting effects without the hematopoietic side effects of full EPO. It has been studied in neuropathic pain, sarcoidosis, and tissue protection contexts. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.

Mechanism Biological Effect
Activation of tissue-protective EPO receptor subunits Cytoprotection without erythropoiesis
Anti-inflammatory signaling Reduced cytokines & immune activation
Anti-apoptotic pathways (PI3K/Akt) Enhanced cell survival
Immunomodulation Lower chronic inflammation
Endothelial support Improved microvascular function
Repair/regeneration signals Tissue recovery
Candidate Profile

Who It's Designed For

Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with ARA-290 protocol candidates in clinical practice:

Neuropathic Pain

Individuals with physician-confirmed neuropathic pain where ARA-290's TPR activation may be clinically relevant.

Nerve Recovery

Individuals recovering from peripheral nerve injury or damage under physician supervision.

Inflammatory Conditions

Individuals with chronic inflammatory conditions where non-erythropoietic EPO receptor activation may support tissue protection.

Recovery Protocol

Individuals with tissue damage or vascular compromise seeking physician-supervised cytoprotective support.

Determine your candidacy

A physician will review your intake and make eligibility determination within 24–48 hours.

Outcomes & Timeline

What the Clinical Literature Indicates

All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.

Weeks 1–4
Early-stage signaling activity may be observed. Individual outcomes may differ. Physician monitoring recommended.
Weeks 4–8
In clinical and preclinical settings, progressive effects have been associated with continued administration. Results vary by individual.
Weeks 8–12
Sustained physician-supervised administration may support continued outcomes. Your physician will evaluate protocol continuation.
Dosing Overview

Protocol Structure

Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.

Typical Range

4 mg 3x/week

Administration

Subcutaneous injection

Duration

4–12 weeks (physician-determined)

Frequency

3x weekly (physician-determined)

These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.

What's Included

Your Protocol Package

Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD

Valid prescription — Issued by your attending physician upon protocol approval

Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner

Follow-up check-in — Physician review at protocol midpoint; reorder pathway established

Clinical Considerations

Contraindications & Safety Notes

Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.

History of thrombosis: EPO receptor activity reviewed carefully in thrombosis history contexts. Full disclosure required.
Pregnancy or lactation: Not indicated. Contraindicated.
Hematologic conditions: EPO receptor agonists reviewed carefully in polycythemia or clotting disorder contexts.
Current medications: Disclose all medications at intake.
FAQ

Common Questions

This compound is not FDA-approved as a drug. It is dispensed as a compounded medication through licensed 503A compounding pharmacies operating under FDA guidelines. All Verum Health protocols require a valid physician prescription.
After completing your HIPAA-secure health intake, a physician or NP will review your medical history, current medications, goals, and contraindications. If you're a candidate, a virtual consultation is scheduled — typically 15–20 minutes. Turnaround is 24–48 hours from intake submission.
Protocol stacking is reviewed on a case-by-case basis during your physician consultation. Any combination protocol is evaluated for safety and clinical appropriateness. Do not combine protocols without explicit physician guidance.
Reorders are managed through your patient portal. A follow-up physician check-in is required at protocol completion before continuation is authorized. Reorder notification is sent 10 days before your protocol completes.
ARA-290
VERUM HEALTH
From $160
Prescription required
Begin Consultation
How it works:
Add to cart → complete physician intake → doctor reviews within 24–48h → approval → pharmacy ships direct.
Refill Policy: Approved protocols include 4 months of refills. Auto-refill available after initial approval.